An Observational Study on the Prevalence of Human Papillomavirus Types in Women in the Kingdom of Bahrain
NCT ID: NCT01205412
Last Updated: 2012-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
552 participants
OBSERVATIONAL
2010-10-31
2011-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Assessed Cohort
Subjects attending out-patient health services for routine cervical screening or presenting for post-natal check up
Endocervical samples
Endocervical samples collection during routine gynaecological examinations
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Endocervical samples
Endocervical samples collection during routine gynaecological examinations
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women ≥ 16 years of age presenting for post-natal check-ups
* Women providing a cervical sample
* Written informed consent or oral-witnessed thumb printed informed consent obtained from the subject
Exclusion Criteria
* Abundant menstrual bleeding or vaginal discharge not allowing appropriate screening to be performed (Note: Enrolment can be delayed until this condition is resolved)
* Pregnant women
* History of hysterectomy
* Known diagnosis of immunosuppression, or patient on immunosuppressives
* Having received one or more doses of human papillomavirus vaccine prior to participating in the study
16 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Manama, , Bahrain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Moosa K, Alsayyad AS, Quint W, Gopala K, DeAntonio R. An epidemiological study assessing the prevalence of human papillomavirus types in women in the Kingdom of Bahrain. BMC Cancer. 2014 Dec 3;14:905. doi: 10.1186/1471-2407-14-905.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
112710
Identifier Type: -
Identifier Source: org_study_id